Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $86.2 million.

  • Fortress Biotech's Cash & Current Investments rose 4649.72% to $86.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.2 million, marking a year-over-year increase of 4649.72%. This contributed to the annual value of $57.3 million for FY2024, which is 2924.12% down from last year.
  • Fortress Biotech's Cash & Current Investments amounted to $86.2 million in Q3 2025, which was up 4649.72% from $74.4 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Cash & Current Investments ranged from a high of $305.7 million in Q4 2021 and a low of $57.3 million during Q4 2024
  • Its 5-year average for Cash & Current Investments is $155.7 million, with a median of $91.3 million in 2025.
  • As far as peak fluctuations go, Fortress Biotech's Cash & Current Investments soared by 11324.89% in 2021, and later plummeted by 6863.7% in 2023.
  • Over the past 5 years, Fortress Biotech's Cash & Current Investments (Quarter) stood at $305.7 million in 2021, then tumbled by 41.69% to $178.3 million in 2022, then plummeted by 54.6% to $80.9 million in 2023, then decreased by 29.24% to $57.3 million in 2024, then soared by 50.56% to $86.2 million in 2025.
  • Its Cash & Current Investments stands at $86.2 million for Q3 2025, versus $74.4 million for Q2 2025 and $91.3 million for Q1 2025.